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Abstract
Introduction: The present investigation aims to elucidate the effects of Z56822977 on biosynthesis of serotonin in the brain of rats in the 
conditions of monosodium glutamate (MSG)-induced obesity. 
Material and methods: Eighteen male rats were used in the present study and divided into three groups: 1 — control group, 2 — MSG 
group, 3 — MSG + Z56822977 group. Newborn rats of groups 2 and 3 were administered MSG dissolved in saline at the dose 4 mg/g body 
weight with a volume of 8 μl/g s.c. on days 2, 4, 6, 8, and 10 of life. Group 3 received an aqueous solution of Z56822977 a in dose 25 mg/kg 
at volume 1 ml/kg per os. Administration was started at the end of the fourth week after birth and continued intermittently by alternating 
a one-week course with three-week intervals of non-treatment. The MSG-group, respectively, received 1 ml/kg of water per os. Within 
four months after birth, rats were on a standard diet. The content of serotonin, tryptophan, 5-hydroxytryptophan (5-HTr), and activity 
of tryptophan hydroxylase (TRH), amino acid decarboxylase (AADC), and monoaminoxidase (MAO) were determined in brain tissue. 
Results: We have shown that administration of Z56822977 has a positive effect on the main indicators of obesity, as shown by changes in 
key physiological and biochemical parameters (body weight decreased by 13% vs. MSG (p < 0.05); body mass index (BMI), Lee index, and 
visceral fat mass decreased by 18%, 7%, and 55%, respectively (p < 0.05), in comparison with the MSG group). Content of tryptophan and 
serotonin significantly decreased (p < 0.05) in rats with MSG-induced obesity. Also, studies have shown an increase in MAO activity by 97% 
(p < 0.05) and decrease of TRH and AADC activity by 44% and 53%, respectively, (p < 0.05) in the brains of rats with obesity. Z56822977 in-
creased the content of serotonin and tryptophan in rat brains and restored the activity of enzymes (MAO, TRH, AADC) to the control values.
Conclusions: It is known that under conditions of obesity there is a disruption in the functioning of the serotonin system in the brains 
of rats. However, the administration of Z56822977 leads to normalisation of the serotonin and tryptophan content and normalisation of 
the activity of enzymes involved in the pathway of biosynthesis and the breakdown of serotonin. Thus, the administration of Z56822977, 
which affects the serotonergic system, can be used in the treatment of MSG-induced obesity in rats. Z56822977 can be considered as 
a possible novel therapeutic agent, but further studies are needed to confirm its action. (Endokrynol Pol 2018; 69 (5): 536–544)
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Streszczenie
Wstęp: Badanie przeprowadzono w celu wyjaśnienia wpływu Z56822977 na biosyntezę serotoniny w mózgu szczurów z otyłością wy-
wołaną podawaniem glutaminianu sodu (monosodium glutamate, MSG). 
Materiał i metody: W badaniu wykorzystano 18 samców szczura. Zwierzęta podzielono na trzy grupy: 1 — grupa kontrolna, 2 — grupa 
MSG, 3 — grupa MSG + Z56822977. Szczurzym oseskom w grupie 2 i 3 podawano podskórnie MSG rozpuszczony w soli fizjologicznej 
w dawce 4 mg/g masy ciała w objętości 8 μl/g w 2., 4., 6., 8. i 10. dniu życia. Grupie 3 podawano doustnie wodny roztwór Z56822977 
w dawce 25 mg/kg w objętości 1 ml/kg. Pierwszą dawkę Z56822977 podawano po ukończeniu 4 tygodni życia, a następnie kontynuowa-
no podawanie badanej substancji cyklicznie wedlug schematu tydzień podawania substancji badanej/3 tygodnie przerwy. Zwierzętom 
z grupy MSG podawano odpowiednio 1 ml/kg wody doustnie. Przez pierwsze 4 miesiące życia szczury otrzymywały standardową karmę. 
Zmierzono zawartość serotoniny, tryptofanu i 5-hydroksytryptofanu (5-HTr) oraz aktywność hydroksylazy tryptofanowej (tryptophan 
hydroxylase, TRH), dekarboksylazy aminokwasów (amino acid decarboxylase, AADC) i monoaminooksydazy (MAO) w tkance mózgowej. 
Wyniki: Wykazano, że podawanie Z56822977 ma pozytywny wpływ na główne wskaźniki otyłości, co odzwierciedlają zmiany podsta-
wowych parametrów fizjologicznych i biochemicznych [zmniejszenie masy ciała o 13% vs. MSG (p < 0,05); zmniejszenie wskaźnika 
masy ciała (body mass index, BMI), wskaźnika Lee oraz masy tkanki tłuszczowej trzewnej odpowiednio o 18%, 7% i 55%, (p < 0,05) 
w porównaniu z grupą MSG]. Zawartość tryptofanu i serotoniny była istotnie niższa (p < 0,05) u szczurów z otyłością wywołaną 
przez MSG. W badaniach wykazano, że u otyłych szczurów aktywność MAO zwiększa się o 97% (p < 0,05), a aktywność TRH i AADC 
odpowiednio o 44% i 53% (p < 0,05). Podawanie Z56822977 powodowało zwiększenie zawartości serotoniny i tryptofanu w mózgach 
szczurów i przywracało poziom aktywności enzymów (MAO, TRH, AADC) do wartości mierzonych u zwierząt kontrolnych.
Wnioski: Wiadomo, że otyłość wiąże się z zaburzeniem syntezy serotoniny w mózgu szczurów. Jednak podawanie Z56822977 prowadzi 
do normalizacji stężenia serotoniny i tryptofanu oraz przywrócenia prawidłowej aktywności enzymów uczestniczących w biosynte-
zie i degradacji serotoniny. Podawanie Z56822977, cząsteczki wpływającej na układ serotoninergiczny, może powodować korzystne 
efekty w leczeniu otyłości wywołanej przez MSG u szczurów. Można rozważać zastosowanie cząsteczki Z56822977 jako nowego leku 
stosowanego w otyłości, jednak konieczne są dalsze badania w celu potwierdzenia jej działania. (Endokrynol Pol 2018; 69 (5): 536–544)
Słowa kluczowe: serotonina, Z56822977, glutaminian sodu, mózg, receptor wolnych kwasów tłuszczowych GPR40
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an inhibitory influence of brain serotonin (5-HT) on 
feeding behaviour [19–21]. Also, there are additional 
studies that indicate a potential role for brain 5-HT of 
being in control of human eating behaviour as well [19].
Also, previous studies have shown the involvement 
of serotonin in the mechanisms of obesity and diabetes 
[22]. In addition, disruption of serotonergic function 
has been described in animal and human obesity. 
A low activity level was indicated by the findings of 
diminished 5-HT turnover in the hypothalamus of ge-
netically obese Zucker rats [23], HCD (high-calorie diet)-
induced obesity rats [24, 25], and in obese humans [26]. 
On the other hand, there are reports suggesting that 
an impaired functioning of neurotransmitter systems 
(e.g. exacerbated 5-HT response to food intake in the 
ventromedial nucleus [VMH] of obese Zucker rats) may 
also contribute to the impaired energy balance [27–29].
Being the most widely distributed neurotransmitter 
in the brain, it regulates a wide range of functions in-
cluding sleep, depression, anxiety, aggression, appetite, 
temperature, sexual behaviour, and pain sensations. Con-
sequently, the impairment of serotonergic production or 
signalling leads to a large spectrum of pathologies such 
as anxiety, depression, schizophrenia, and obesity [29].
Hence, it was interesting to investigate the state of the 
serotoninergic system in the brain of animals with obe-
sity, induced by the administration of MSG itself, which 
causes lesions in the hypothalamic arcuate nucleus (ARC) 
and impairs leptin and insulin signalling in this region, 
resulting in hyperleptinaemia and hyperinsulinaemia.
Obesity is associated with chronic low-grade inflam-
mation, which drives the development of metabolic 
diseases, including NAFLD. That is why the search for 
non-toxic drugs to prevent an obesity complication, 
namely inflammation, is of current interest. A new 
potential target for treatment of type 2 diabetes (T2D) 
is free fatty acid receptor 1 [30–32].
In high-glucose conditions β-oxidation is inhibited 
by a product of the glycolytic pathway, malonyl-CoA, 
and fatty acids are directed towards the formation of 
triacylglycerol (TAG) [33, 34]. The anabolic and catabolic 
reactions between long-chain acyl Co-As (LC-CoA) and 
TAG, known as glycerolipid/free fatty acid (GL/FFA) 
cycle, produce lipid signalling molecules that stimulate 
insulin secretion [35]. In addition, FFAs serve as ligands 
and influence insulin secretion by interacting with 
G-protein-coupled receptors (GPCRs) on the plasma 
membrane [36, 37]. One of the GPCRs that is highly 
expressed in beta cells is free fatty acid receptor 1 (FFAR1 
or GPR40) [36, 37]. Activation of the receptor leads to en-
hanced insulin secretion by activating protein kinase C 
(PKC) and triggering ER Ca2+ release [38, 39]. Recently, 
FFAR1 agonists have been developed as potential thera-
peutic agents for the treatment of type 2 diabetes [40–43]. 
Introduction 
The central nervous system has developed a meticulously 
interconnected circuitry to meet keeping fed and an ad-
equate nutritional state. An energy-dense environment 
favours the development of obesity, whilst overcompen-
sation may shut down the drive to feed [1]. In today’s 
society, where evolving disease demographics and life-
style allow for a greater diversity of metabolic phenotypes 
than perhaps ever before [2], disorders of both extremes 
of energy intake are common in health care.
Obesity is increasing at an alarming rate in industri-
alised and developing countries alike [3] and is associ-
ated with a wealth of conditions afflicting virtually all 
organ systems [4, 5]. Overweight or obesity is a condi-
tion that substantially raises the risk of morbidity from 
hypertension, dyslipidaemia, type 2 diabetes, coronary 
heart disease, stroke, gallbladder disease, osteoarthritis, 
sleep apnoea and respiratory problems, and endome-
trial, breast, prostate, and colon cancers [6, 7]. At first 
sight, obesity, unlike many other common diseases, 
has an obvious solution: adjusting food intake and 
exercise until normal body weight has been restored. 
However, it is no great revelation that this solution is 
as simple as it has repeatedly proved to be elusive [8]. 
Experimental studies confirm the common knowledge 
that weight loss is almost always followed by a rapid 
return to initial weight once the anorexigenic regimen 
is terminated [9]. Available options for pharmacological 
therapy leave much to be desired, and compounds that 
have been introduced for obesity management have 
subsequently often been withdrawn due to intolerable 
side-effects [10]. Novel treatments are greatly needed.
Experimental studies [11–15] demonstrated that 
damage to particular regions of the hypothalamus and 
brainstem leads to profound alterations in feeding be-
haviour. It also became apparent that the signals from 
the peripheral energy stores [16] and gastrointestinal 
canal [17] provide essential cues for appetite and satiety. 
Metabolic state is reflected in a diverse array of signals of 
the brain. Recent investigations have shed light on some 
of the key hormones and the vagal mechanisms that 
shape the central response to nutritional challenges. 
A link between food ingestion and brain monoamine 
systems may exist for substances in the blood, including 
such hormones as insulin and corticosterone (CORT), 
which are important in energy metabolism, are closely 
associated with feeding behaviour, and are known to 
influence neurotransmitter function in the brain. The 
release of insulin, for example, occurs in association with 
food intake [18] and, through its effects on tryptophan, 
increases the synthesis of 5-HT in the brain. Pharma-
cological, biochemical, and behavioural evidence has 
accumulated in animals in support of the idea about 
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A general problem with currently known FFA1 
ligands is their relatively high lipophilicity, which is as-
sociated with numerous problems such as poor pharma-
cokinetic properties, metabolic instability, toxicity, and 
off-target effects, and correlates with attrition in clinical 
trials [44–47]. Therefore, it is advisable to continue the 
search and to research agonists for FFA1 with the focus 
on lowering lipophilicity [48–50].
Taking into account the aforementioned, we decided 
to investigate the effects of FFA1 agonist on the rat 
model of MSG-induced obesity in rats.
Material and methods
Research was conducted in compliance with the stand-
ards of the Convention on Bioethics of the European 
Convention for the Protection of Vertebrate Animals 
adopted by the Council of Europe, which is applicable 
for experimental and other scientific purposes’ (1997), 
the general ethical principles of animal experiments, 
approved by the First National Congress on Bioethics 
in Ukraine (September 2001), and other international 
agreements and national legislation in this field. The 
animals were kept in a vivarium, which was accredited 
in accordance with the ‘standard rules on ordering, 
equipment, and maintenance of experimental biological 
clinics (vivarium)’. All the equipment that was used for 
the research had been subjected to metrological control. 
Animals and housing conditions
In our investigation, 18 newly born male rats were includ-
ed and divided into three groups of six animals each. The 
animals of each study group were individually housed in 
polypropylene cages in an environmentally controlled 
clean air room, with the temperature of 22 ± 3°C, 12 h 
light/12 h dark cycle, and at a relative humidity of 60 ± 5%.
Synthesis procedure [51]
Monobenzyl ether of hydroquinone (5 mmol, Z1) was 
dissolved in 20 ml of dry acetone followed by the ad-
dition of 7.5 mmol of dry K2CO3. Then, Table I. Orga-
nometric parameters of glutamate-induced obesity rats 
and corrected parameters by Z56822977-bromoacetic 
acid ethyl ester (5.5 mmol) was added dropwise (Z2) 
and the mixture was refluxed for four hours. The sol-
vent was removed using rotary evaporator and the 
residue was crystallised from ethanol with a yield of 
1.35 g (96%, Z3).
Compound Z3 (1.35 g, 4.8 mmol) was dissolved by 
stirring in 10 ml of 30% aqueous solution of NaOH 
at 50°C. After the Z3 was completely dissolved, 
the reaction mixture was stirred for one hour then 
acidified with a 10% solution of HCl to pH = 2. The 
formed precipitate was filtered off, washed with water 
(3 x 10 ml), dried on air, and crystallised from ethanol. 
The yield was 1.15 g (93%, Z56822977 (2-[4-(benzyloxy)
phenoxy]acetic acid)).
Animals and experiment design
Newborn rats of group 1 (Control) were injected 
with saline at a volume of 8 μl/g subcutaneously 
(s.c.) on days 2, 4, 6, 8, and 10 of life. Newborn rats 
of groups 2 and 3 were administered with MSG dis-
solved in saline at a dose of 4 mg/g of body weight 
with a volume of 8 μl/g s.c. on days 2, 4, 6, 8, and 10 
of life [52–55]. The rats were on a standard diet for 
the entire study period. Group 3 received an aque-
ous solution of Z56822977 at a dose of 25 mg/kg 
at a volume of 1 ml/kg per os. Administration was 
started at the end of the fourth week after birth and 
continued intermittently by alternating a one-week 
course with three-week intervals of non-treatment. 
The MSG-group respectively received 1 ml/kg of 
water per os.
Biochemical, anthropometrical and nutritional 
determinations
During the four months after birth we analysed the 
changes of body weight in all groups. In adult age, 
rats from three experimental groups were weighed 
and sacrificed. We weighed all animals, measured their 
nose-to-anus length, and calculated body mass index 
based on the formula below. 
Body mass index (BMI) = body weight [g] / (nose-
to-anus length)2 [cm2]
For each animal at the fourth month after birth we 
determined the obesity status using the Lee index [56]. 
Lee index = cube root of body weight [g] / nose-to- 
-anus length [cm]. 
Adult animals were sacrificed. The rats’ brains were 
removed and weighed. Brains were homogenised 
in 0.4 M perchloric acid at the rate of 5 ml buffer per 
half of the brain. Samples were kept at 4°C for 60 min 
and then centrifuged at 0°C for 5 min at 800×g. After 
centrifugation the supernatant was collected and the 
pH was adjusted to 5–6 using 2 M KOH. Samples were 
centrifuged for 5 min at 800×g at a temperature of 0°C. 
Serotonin and tryptophan content in the brain 
The tryptophan content in the brain was determined 
using ion-exchange chromatography and fluorescence 
methods, which were described previously [57]. 
The resulting supernatant was applied to a pre-
equilibrated 0.01 M Na-phosphate buffer, pH 6.2, 
the column of CM-Sepharose. Elution was carried 
with 0.03 M sodium phosphate buffer, pH 6.2. To 
1 ml fraction of serotonin was added 0.3 ml of 11.6 M 
HCl. Measurements were performed on a Shimadzu 
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spectrophotofluorometer at an excitation wavelength 
of 295 nm and emission wavelength of 550 nm against 
a blank sample that contained distilled water instead 
of the test sample. 
Then elution was carried out with 0.01 M sodium 
phosphate buffer, pH 6.2. To 0.5 ml fraction of tryp-
tophan was added 0.5 ml of a dithiothreitol mixture: 
ethanol (1 mg dithiothreitol/1 ml of ethanol) and 0.5 ml 
of ninhydrin reagent (ninhydrin dissolved in a solution 
of 17.4 M acetic acid and 3 M phosphoric acid in the ratio 
3: 2). Samples were placed in a boiling water bath for 
25 minutes and then cooled under running water. Meas-
urements were performed on spectrophotofluorometer 
at an excitation wavelength of 359 nm and emission 
wavelength of 485 nm against the blank sample that 
contained distilled water instead of the test sample.
5-hydroxytryptophan content in the brain
The 5-hydroxytryptophan content in the brain was 
determined using the fluorescence method described 
previously [58]. 
0.5 ml of the resulting supernatant was added to 
2.5 ml of 1 N perchloric acid and stirred vigorously 
for 5 min. Samples were centrifuged at 2000 g for 30 
min. The resulting supernatant was collected and ad-
justed to pH 9.5–10.5 with a 5 M NaOH solution. Then 
2.5 ml of n-heptane saturated with NaCl was added, 
and intensively stirred for 15 min. For phase separation 
a sample was centrifuged for 3 min at 500 g. 1 ml of 
the aqueous phase was collected, and 0.3 ml of 11.6 M 
HCl was added. Measurements were performed on 
a Shimadzu spectrophotofluorometer (excitation 295 
nm, emission 545 nm). 
Tryptophan hydroxylase activity in the brain
Determination of tryptophan hydroxylase activity was 
performed according to the method recommended in [59].
The complete reaction mixture contained the 
following components in a final volume of 0.37 ml: 
50 mM Tris-acetate pH 7.5; 0.3 mM L-tryptophan; 
0.1 mM GMPHa; 0.05 mM TPNH; 0.5 mM glucose-
6-phosphate; 0.7 mM N-methyl-N-3.hydroxyphenyl-
hydrazine; 0.4 mM dithiothreitol; catalase, glucose-
6-phosphate dehydrogenase and dihydropteridine 
reductase in excess, and an appropriate amount of 
hydroxylase, usually 0.04 ml to 0.2 ml. After 30 min of 
incubation in a shaking water bath at 37°C, the reaction 
was stopped by the addition of 0.03 ml of 60% perchlo-
ric acid and the mixture was centrifuged. Precisely 
0.2 ml of the supernatant fraction was added to 0.06 ml 
of concentrated hydrochloric acid. The amount of 
product, 5-hydroxytryptophan, was measured fluoro-
metrically with a Shimadzu spectrophotofluorometer 
(excitation 295 nm, emission 538 nm). 
Tryptophan-decarboxylase activity in the brain
Determination of tryptophan decarboxylase activity 
was carried out by the spectrofluorimetric method 
described previously [60].
Brains were homogenised in 0.4 M perchloric acid in 
a ratio of 1: 5 (w/v). Homogenate was kept for 60 min at 
4°C and then centrifuged for 5 min at 800 g. The pH of 
the supernatant was adjusted to 5–6 with 2 M KOH and 
centrifuged for 5 min at 800 g. 100 μl of the supernatant was 
collected and was adjusted up to 1 ml by 100 mM Tris-HCl 
buffer, pH 8.0, containing 5 mM β-mercaptoethanol, 10% 
glycerol. Subsequently, 2 ml of 4 mM NaOH and 5 ml of 
ethyl acetate were added and samples were placed for 
30 seconds. For phase separation samples were centrifuged 
for 2 min at 252 g. The determination of tryptophan- 
-decarboxylase activity was performed in the organic phase. 
Measurements were performed on a Shimadzu spectro-
photofluorometer (excitation 280 nm, emission 340 nm).
Monoamine oxidase activity in the brain
Monoamine oxidase activity was estimated according to 
the method of Ali and Bartlet, in which the production 
of 4-hydroxyquinoline from the oxidative deamination 
of kynuramine is measured [61].
The incubation mixture contained kynuramine di-
hydrobromide (100 mkg) 0.5 M phosphate buffer pH 7.4 
(0.5 ml), homogenate (equivalent to 3.13 mg brain), and 
de-ionised water to a final volume of 3 ml. An incubate 
without a substrate served as a blank. The reaction 
mixtures were incubated at 37°C for 30 min under air 
and with shaking. The incubates were then deprotein-
ised with perchloric acid (0.6 M) as recommended by 
Century and Rupp (1968) followed by centrifugation at 
900 g for 10 min at 5°C. Supernatant (1 ml) was mixed 
with 1 N NaOH (2 ml) and placed in a quartz cuvette. 
The solution was activated at 315 nm, and the peak in 
the fluorescence scanned at 380 nm was measured on 
a Shimadzu spectrophotofluorometer. The presence of 
substances affecting the fluorescence of 4-hydroxyqui-
noline was sought by mixing equal volumes of tissue 
blank and 4-hydroxyquinoline solution. In all cases the 
fluorescence of the mixture was half that of the undi-
luted solution of 4-hydroxyquinoline, demonstrating an 
absence of augmentation or quenching of fluorescence.
Statistics
Statistical analysis was performed using Statistica 7 
software. All data in this study were expressed as mean 
± standard error (M ± SEM). Data distribution was 
analysed using the Kolmogorov-Smirnov normality test. 
Continuous variables with parametric distribution were 
analysed using Analysis of Variance (ANOVA), and if 
the results were significant, a post-hoc Turkey’s test was 
performed. For data with non-parametric distribution 
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the Kruskal-Wallis and post-hoc Tukey’s test were con-
ducted for multiple comparisons. For comparisons of 
categorical variables, we conducted the chi-squared test. 
The difference between groups was defined as statisti-
cally significant when the p-value was less than 0.05.
Results
Body parameters and visceral adipose tissue 
mass in the conditions of Z56822977 treatment of 
MSG-induced obesity
Administration of MSG in the neonatal period leads 
to the development of obesity in four-month-old rats. 
Table I shows the organo-metric parameters in three 
groups of rats. Administration of MSG in the neonatal 
period caused a significant increase in index Li and BMI 
of rats, in comparison with the control rats. The weights 
of adipose tissue (subcutaneous, gonadal, and visceral) 
were significantly higher in the MSG group than those 
in the control group. A number of differences in body 
parameters in the MSG group treated with Z56822977 
was found. Treatment with Z56822977 (25 mg/kg) signifi-
cantly suppressed the increase in body weight, index 
Li, and BMI of MSG-obese rats. Z56822977 (25 mg/kg) 
treatment significantly lowered the adipose tissue when 
compared to the MSG group and control group (Table I).
Serotoninergic system assessment in the 
conditions of Z56822977 treatment of MSG- 
-induced obesity
The level of serotonin in brain homogenate of MSG-
induced rats showed a significant decrease (55.14%) 
compared to that of control rats. The oral administra-
tion of Z56822977 to group III rats showed a significant 
increase in the level of brain serotonin (63.8%) com-
pared to MSG-induced obese rats (Figure 1). The level 
of tryptophan in the brain of rats with MSG-induced 
obesity decreased (56.25%) (Figure 2). The research 
of a rate-limiting enzyme of serotonin biosynthesis 
(tryptophan-hydroxylase) activity in the brains of 
rats with the experimental model of obesity showed 
a decrease in enzyme activity by 44.4% in compari-
son with the values of the control group (Figure 3). 
Treatment with Z56822977 (25 mg/kg) significantly 
increased tryptophan-hydroxylase activity of MSG- 
-obese rats. The analysis of the brain 5-HTr content 
showed a decrease of this indicator in MSG-induced 
obese rats compared to intact animals. Z56822977 
(25 mg/kg) treatment does not affect the content of 5-HTr 
when compared to the MSG group and control group 
(Figure 4). According to the data presented in Figure 5, 
tryptophan-decarboxylase activity was decreased by 
53.2% in the rats under MSG-induced obese rats. Stud-
ies have shown an increase in MAO activity of 96.5% in 
the brains of rats with experimental obesity compared 
with the values of the control group (Figure 6).
Discussion
Hypothalamic centres have been reported to integrate 
information about long-term energy stores and other 
physiological and environmental factors to formulate 
appropriate feeding responses. Serotonin influences 
both brainstem reflex centres and hypothalamic integra-
tory centres involved in controlling food intake.
We found that MSG-obese rats neonatally treated 
with MSG exhibited obesity with reduced body weight 
and body length and increased Lee index and BMI, com-
pared to control rats neonatally treated with saline. An 
increase in adipose tissue weight was also found in the 
rats with obesity induced by neonatal injection of MSG. 
MSG-obese rats have a reduced body weight compared 
Table I. Organometric parameters of glutamate-induced obesity rats and corrected parameters by Z56822977
Tabela I. Parametry organometryczne zmierzone u szczurów z otyłością wywołaną przez podanie glutaminianu sodu oraz 
poprawa tych parametrów po podaniu Z56822977
Intact rats MSG-induced obesity
Placebo Z56822977
Body weight [g] 385.5 ± 28.402 339.1 ± 18.755 294.8 ± 24.383*
Body length [cm] 24.2 ± 0.935 20.8 ± 0.605* 21.4 ± 0.97*
Index Lee 0.3 ± 0.006 0.335 ± 0.006* 0.311 ± 0.01#
BMI [g/cm2] 0.655 ± 0.019 0.781 ± 0.035* 0.643 ± 0.041#
Subcutaneous adipose tissue, g/100 g body weight 9.873 ± 2.797 51.464 ± 10.471* 26.2 ± 8.549#
Gonadal adipose tissue, g/100 g body weight 6.782 ± 1.782 26.25 ± 6.627* 16.77 ± 5.47#
Visceral adipose tissue, g/100 g body weight 4.759 ± 1.011 34.05 ± 6.908* 15.326 ± 6.561#
*p < 0.05 differences significant compared to controls 
#p < 0.05 differences significant compared to MSG-induced obesity
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Figure 2. Content of tryptophan (μg/g tissue) in brain tissue in the 
condition of MSG-induced obesity and treatment with Z56822977 
(M ± SEM, n = 6 in each group). 1 — intact rats, 2 — MSG-group, 3 — 
MSG + Z56822977 group. *p < 0.05 differences significant compared 
to controls; #p < 0.05 differences significant compared to MSG-induced 
obesity
Rycina 2. Stężenie tryptofanu (μg/g tkanki) w mózgu szczurów 
z otyłością wywołaną MSG leczonych Z56822977 (M ± SEM, 
n = 6 w każdej grupie). 1 — szczury niepoddane interwencji, 
2 — grupa MSG, 3 — grupa MSG + Z56822977
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Figure 3. Tryptophan hydroxylase (TPH) activity in brain tissue 
in the condition of MSG-induced obesity and treatment with 
Z56822977 (M ± SEM, n = 6 in each group). 1 — intact rats, 
2 — MSG-group, 3 — MSG + Z56822977 group. *p < 0.05 
differences significant compared to controls; #p < 0.05 differences 
significant compared to MSG-induced obesity
Rycina 3. Aktywność hydroksylazy tryptofanowej (tryptophan 
hydroxylase, TRH) w tkance mózgowej szczurów z otyłością 
wywołaną MSG leczonych Z56822977 (M ± SEM, n = 6 
w każdej grupie). 1 — szczury niepoddane interwencji, 2 — grupa 
MSG, 3 — grupa MSG + Z56822977
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Figure 4. Content of 5-hydroxytryptophan (units/g tissue) 
in brain tissue in the condition of MSG-induced obesity and 
treatment with Z56822977 (M ± SEM, n = 6 in each group). 
1 — intact rats, 2 — MSG-group, 3 — MSG + Z56822977 
group. *p < 0.05 differences significant compared to controls; 
#p < 0.05 differences significant compared to MSG-induced obesity
Rycina 4. Stężenie 5-hydroksytryptofanu (j./g tkanki) w tkance 
mózgowej szczurów z otyłością wywołaną MSG leczonych 
Z56822977 (M ± SEM, n = 6 w każdej grupie). 1 — szczury 
niepoddane interwencji, 2 — grupa MSG, 3 — grupa MSG + 
Z56822977
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Figure 1. Content of serotonin (ng/g tissue) in brain tissue in the 
condition of MSG-induced obesity and treatment with Z56822977 
(M ± SEM, n = 6 in each group). 1 — intact rats, 2 — MSG- 
-group, 3 — MSG + Z56822977 group. *p < 0.05 differences 
significant compared to controls; #p < 0.05 differences significant 
compared to MSG-induced obesity
Rycina 1. Stężenie serotoniny (ng/g tkanki) w tkance mózgowej 
szczurów z otyłością wywołaną MSG leczonych Z56822977 
(M ± SEM, n = 6 w każdej grupie). 1 — szczury niepoddane 
interwencji, 2 — grupa MSG, 3 — grupa MSG + Z56822977
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to intact animals. However, most of the MSG-obese 
rats can be identified by their ‘fatty feel’ due to their 
greatly increased adiposity and by their changed body 
shape. Our results are consistent with the results of 
many studies [62–65].
According to literature data, obesity is characterised 
by increased levels of circulating proinflammatory cy-
tokines, accumulation of leukocytes within the adipose 
tissue and other organs, activation of macrophages in the 
liver and fat, and activation of proinflammatory [66, 67]. 
Previous studies have been installed the increase of 
content of pro-inflammatory cytokines in MSG-obese 
rat serum [68]. Cytokines like IL-6 and TNF-α promote 
insulin resistance by increasing hepatic suppressors of 
cytokine signalling expression [69].
The activation of systemic inflammatory processes, 
originating from alterations in adipose tissue and 
gut functions, can contribute to the development of 
obesity-associated neuropsychiatric comorbidities. 
Proinflammatory cytokines released at the periphery 
can access the brain via several pathways (e.g. neural, 
humoral, and cellular routes) and induce the activation 
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of neuroinflammatory processes, primarily by activating 
microglia. In the brain, proinflammatory cytokines im-
pair neuroendocrine activity, neurotransmitter function 
(e.g. 5HT, DA, glutamate), and neurocircuitry, involving 
notably the hippocampus, the hypothalamus, the basal 
ganglia, and the prefrontal cortex. IFN-α induces major 
depression, and this effect relates to inflammation-
induced alterations in the hypothalamic–pituitary– 
–adrenal (HPA) axis, neurotransmitter function, and 
enzymatic pathways involved in the metabolism of 
monoamines [70–74].
The decreases in serotonin and its metabolite con-
centrations in the tissue of MSG-obese rats appear to be 
attributable to the destruction of the VMH and ARC in 
the hypothalamus. Slight decreases in the concentration 
of serotonin and its metabolite in the brain observed after 
administration of Z56822977 to MSG-obese rats were 
assumed to be due to the serotonin uptake inhibition by 
Z56822977 in the hypothalamic areas that had not been 
destroyed, which promoted the function of the serotonin 
nervous system by increasing serotonin levels in synapses.
Clearly, serotonin levels in the brain are highly 
dependent on levels of 5-HTP and LT in the central 
nervous system (CNS) [75]. Synthesis of serotonin is 
heavily dependent upon the availability of tryptophan 
within the central nervous system. The production and 
transport of tryptophan from the bloodstream into the 
central nervous system can be compromised by stress, 
elevated cortisol levels, vitamin B6 deficiency, and high 
dosages of tryptophan. All these factors stimulate the 
conversion of tryptophan to kynurenine, lowering 
serum tryptophan levels [75]. 
Elevated serum levels of kynurenine inhibit trans-
port of tryptophan into the central nervous system and 
reduce central nervous system serotonin levels. This 
may be one of the reasons for the lowering of trypto-
phan levels in the brains of rats under conditions of 
development of MSG-induced obesity. Another reason 
for lowering the content of tryptophan may be competi-
tion with other amino acids for passing the blood–brain 
barrier. The transport of tryptophan through the blood-
brain barrier requires binding to a transport molecule, 
which tryptophan shares with five other amino acids 
(tyrosine, phenylalanine, valine, leucine, and isoleu-
cine). Since tryptophan is present in foods in relatively 
small amounts in comparison to these other amino 
acids, as little as one per cent of dietary tryptophan 
may be transported into the CNS. Tryptophan is used 
by the body for other metabolic purposes in addition 
to serotonin production, including protein synthesis 
and the creation of niacin. The increase of serotonin in 
the brain of animals after administration of Z56822977 
can be explained by interaction of the preparation with 
serotonin transporters, which stimulates the release 
of serotonin from the cytoplasm of the neuron into 
the synaptic cleft. Dedicated serotonin in the synaptic 
cleft is inactivated by reversible capture of serotonergic 
terminals using serotonin transporter and enzymatic 
degradation of serotonin by monoamine oxidase.
The serotonin system is relatively complex. Several 
receptor subtypes, anatomical projections are involved 
in the serotonin system. Ongoing research continues 
to delineate the brain pathways underlying the regula-
tion of body weight by brain serotonin. Much remains 
Figure 5. Amino acid decarboxylase (AADC) activity in brain 
tissue in the condition of MSG-induced obesity and treatment 
with Z56822977 (M ± SEM, n = 6 in each group). 1 — intact 
rats, 2 — MSG-group, 3 — MSG + Z56822977 group. *p < 0.05 
differences significant compared to controls; #p < 0.05 differences 
significant compared to MSG-induced obesity
Rycina 5. Aktywność dekarboksylazy aminokwasów (amino acid 
decarboxylase, AADC) w tkance mózgowej szczurów z otyłością 
wywołaną MSG leczonych Z56822977 (M ± SEM, n = 6 w każdej 
grupie). 1 — szczury niepoddane interwencji, 2 — grupa MSG, 
3 — grupa MSG + Z56822977
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Figure 6. Monoamine oxidase (MAO) activity in brain tissue 
in the condition of MSG-induced obesity and treatment with 
Z56822977 (M ± SEM, n = 6 in each group). 1 — intact rats, 
2 — MSG-group, 3 MSG + Z56822977 group. *p < 0.05 
differences significant compared to controls; #p < 0.05 differences 
significant compared to MSG-induced obesity
Rycina 6. Aktywność monoaminooksydazy (MAO) w tkance 
mózgowej szczurów z otyłością wywołaną MSG leczonych Z56822977 
(M ± SEM, n = 6 w każdej grupie). 1 — szczury niepoddane 
interwencji, 2 — grupa MSG, 3 — grupa MSG + Z56822977
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to be understood about the serotonin projections 
and about the specific roles of each of the serotonin 
receptor subtypes. Greater understanding of seroto-
nergic mechanisms is likely to lead to more efficacious 
serotonin-based pharmacotherapies.
Conclusions 
Our studies confirm the involvement of serotonin in the 
mechanisms of obesity. The results suggest that admini-
stration of Z56822977 inhibited serotonin uptake in the 
brain areas that were not destroyed in MSG-obese rats, 
which increased the function of the serotonin nervous 
system by increasing serotonin levels in synapses and 
thereby suppressed food intake and increased sym-
pathetic nerve activity as well as spontaneous motor 
activity. In this way Z56822977 decreased the Lee index, 
body weight, and adipose tissue weight. 
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